After 1 year, there were no differences in the number of patients who stopped taking their medication or the number of patients who had adverse events or immunogenicity within the first 12 months of the switch.These data support the safety and efficacy of nonmedical infliximab switching in patients with IBD, wrote study author Thomas Tam Hoang, a medical resident at the University of British Columbia Faculty of Medicine in Vancouver, British Columbia, Canada, and colleagues.
"Given that we are one of the first jurisdictions in BC leading the biosimilar switch initiative in Canada, we wanted to see whether there could be any adverse outcomes with switching to biosimilars. That was the main driver for the study. We wanted to help reassure our patients and to help guide other provinces when they eventually go through the switch," he added.The retrospective observational study enrolled stable patients with IBD from the IBD Centre of British Columbia.
All outcomes were similar between the two groups. There was no difference in treatment continuation between the biosimilar group and the originator group .
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FCN2go - 🏆 523. / 51 Read more »
Source: cleantechnica - 🏆 565. / 51 Read more »